Purpose: To analyze the spectrum and frequency of N F 1 mutations in exon lob. Methods: Mutation and sequence analysis was performed at the DNA and cDNA level. Results: We identified nine exon l o b mutations in 232 unrelated patients. Some mutations were recurrent (Y489C and L508P), others were unique (1465-1466insC and IVSlOb+2delTAAG). Surprisingly, at the RNA level, Y489C causes skipping of the last 6 2 nucleotides of exon lob. Another recurrent mutation, L508P, is undetectable by the Protein Truncation Test. Conclusion: A s exon l o b shows the highest mutation rate yet found in any of the 6 0 NF1 exons, it should be implemented with priority in mutation analysis. Genetics in Medicine, 1999:1(6):248-253.
Neurofibromatosis type 1 (NF1, MIM 16,2200) is one of the most common autosomal dominant disorders, affecting about 1:3500 individuals in all ethnic groups. The main characteristics are cutaneous or subcutaneous neurofibromas, cafe-aulait (CAL) skin spots, iris Lisch nodules, and freckling.' Other features found in only a minority of patients include scoliosis, macrocephaly, pseudarthrosis, short stature, malignancies, and learning disabilities. As NFI clinically presents with great variability, even among patients in the same family, the pathogenicity underlying the phenotype must be complex.
The NFI gene has been mapped to 17q11.2 and was positionally cloned.*-"he NFI gene is approximately 350 kb in size, contains 60 exons and codes for a 11-to 13-kb transcript with an open reading frame coding for 2818 amino acids.5 By RT-PCR, NFI mRNA appears to be ubiquitous, but by Western blot, neurofibromin is best detected in neural-crest-derived tissues.
The mutation rate in the NFI gene is one of the highest known in humans (reviewed by Huson and Hughes1 ) with approximately 50% of all NFI patients presenting with new mutations. Despite the high frequency of this disorder in all populations, relatively few mutations have been identified at the molecular level, with most unique to one family. A limited number of mutational "hotspots" have been identified: R1947X (C5839T) in exon 31 and the 4-bp region between nucleotides 6789 and 6792 in exon 37, both implicated in about 2% of the NF1 patients (reviewed by Upadhyaya and Cooper6) . In this study we report that another mutational hot-~ spot resides in exon lob. By analyzing altogether 232 unrelated NF1 patients, we identified 9 mutations in exon lob, indicating that this exon is mutated in almost 4% of NFl patients. So far this is the highest score obtained for a particular exon in the 9 years since the NFI gene was discovered.
MATERIALS AND MnHODS

NF1 patients
For all patients, the diagnosis of NF1 was based on the presence of two or more of the diagnostic criteria proposed by the NIH Consensus Statement in 1988' and updated in 1997.8 The study was approved by the Institutional Ethical Committees and informed consent was obtained from the patients studied. Patients were recruited randomly without bias as they were seen for medical follow up and genetic advice. Patients were recruited as part of a general mutation study. Seventy-three patients were contributed by the Department of Medical Genetics of Gent and by the Service de Genetique, Hopital Erasme, Brussels; 159 patients were contributed by the Departwere obtained from 195 unrelated NF1 patients by extraction from peripheral blood lymphocytes. Total cellular RNA and genomic DNA was isolated as described.' cDNA analysis and in vitro transcriptionAranslation analysis First strand cDNA was synthesized by random priming9 and cDNA was amplified using 5 primer pairs for amplification of the total coding region."' 4 pL PCR product was used in an optimized in vitro transcriptionltranslation reaction as described.'," An identical truncated peptide fragment of 55 kD was observed in 2 of 37 patients by in vitro transcriptionltranslation of the fragment spanning exons 1 to 12a and the corresponding cDNA was analyzed by cycle sequencing with and without subcloning using 0.15 p M fluorescein isothiocyanate (FITC) labeled primers, designated by nucleotide positions: 5'-CTTCGGAATTCTGCCTCT-3' (400-418), 5'-CT-GATATGGCTGAATGTG-3' ( 7 19-73b), 5'-GCCTGTGTCA- , and 5'-CACACCCAGCAATAC- GAA-3' (1367 GAA-3' ( -1384 , and the Thermo Sequenase fluorescent labeled primer cycle sequencing kit (Amersham, Arlington Heights, IL). Samples were loaded on a 6% LongRanger gel (FMC, Rockland, ME) containing 7 M urea and analyzed on an ALF automated DNA sequencer. To check for the presence of the missense mutation Y489C in a fraction of the cDNA, RT-PCR fragments were cloned using the pCR-TOP0 cloning kit (InVitrogen, San Diego, CA) and 90 individual clones were further analyzed by cycle sequencing.
Genomic DNA analysis
Exon lob was amplified using the primer pair as described" and PCR products were further analyzed by cycle sequencing without sub~loning.~ Genomic DNA from 195 unrelated NF1 patients from which no EBV lymphoblastoid cell line was available was analyzed by heteroduplex analysis or single strand conformation analysis or both, and aberrant migrating PCR fragments were further analyzed by cycle sequencing.I3 Mutations are reported according to the recommendations of the Nomenclature Working Group,14 with the start site of translation denoted as nucleotide 1 for both cDNA and genomic alterations.
RESULTS
The total coding region of the NFI gene was analyzed by the protein truncation test in 37 unrelated NFl patients from which an EBV lymphoblastoid cell line was a~ailable.~~' In two patients, an identical shortened fragment of approximately 55 kD was discerned in the region encompassing the exons 1 to 12a. In both patients, in vitro transcription/translation for the other regions only showed normal sized fragments. By electrophoresis of the RT-PCR fragments from Patient 1 two discrete bands were discerned on a 1.5% agarose gel, i.e., a normalsized band of 1868-bp and a band that was approximately 60 bp smaller. In Patient 2, however, only a normal-sized band was seen, indicating that the truncated protein of identical size was formed in a different way in this patient. cDNA sequencing in this region indeed revealed a different mutation in both patients. In Patient 2, an insertion ofC at nt 1465-1466 in exon lob was found, immediately resulting in the creation of a stop codon at this site. In Patient 1, a deletionlskipping of the last 62 nucleotides of exon lob was observed in RNA from both lymphocytes and the EBV-lymphoblastoid cells (Fig. 1B) . Here too, the immediate result is formation of a stop codon at this site, explaining the identical picture seen by protein truncation analysis. Further analysis of exon lob at the genomic level confirmed the presence of an insertion 1465insC in Patient 2. In Patient 1, however, a missense mutation was identified: A1466G, changing the codon for Tyr to Cys (Y489C) (Fig. 1A) . Both parents of this sporadic patient did not carry this missense mutation. This missense mutation masquerades as a splicing defect: indeed substitution of A to G at position 1466 of the genomic DNA creates a new splice donor site (CT/ GTAAG) (Fig. 1C) . Analysis of the normal and mutant se- ~epternber/?&%W 1999 . V o l .~l . No. 6 \ quence using the progrum for splice site prediction by neural network (available ;lt URL: WWW-hgc.lbl.g~v/projects/ splice.html) showed , I 0.8h score for the normal exon lob donor site (C;CTTTGT/gtnagt.lt) c~~i d a higher 0.97 score for the 11ew donor site crcatcci hy the missense mutation Y489C (AGAAGCTlgt,~,lgt,lt). RT-PCR fragments from an EBV lymphoblastoici cell line of P,ttient 1 were cloned and 90 individual clones were further ;ln,llyzcd by cycle sequencing to check for the presence of the missense mutation in a fraction of the cIINA. In 50 cIINA clones showing n normal-sized band of 1868 bp on ' 1 1.5%1 ~lg~irose gel, only the wild type sequence was found and in none of them the nlissense mutation was present. In 40 clones cont'lining J slightly smaller insert (approximately 60 bp) ,~sevidenced by agarose gel electrophoresis, the smaller size was due to the skipping of the last 62 nucleotides of exon lob dong with intron lob in the mRNA (Fig. 1B) . This indicates t h~t the major outcome of the mutation Y489C at the cDNA level is skipping of the last 62 nucleotides of exon lob. Although Y489C ~n d 1465-1166insC are different mutations ~t the genonlic DNA level, both result in the formation of a premature stop codon at exactly the same position well before the GAP domain of neurofibromin. As the finding of two different mutations at the same spot (i.e., 1465-1466insC and 1466A>G) is in itself indicative of a mutational hotspot,15 these findings prompted us to analyze exon lob in a larger patient population consisting of 195 unrelated NF1 patients from which genomic DNA and total RNA was available but no EBV lymphoblastoid cell line. In Patients 3, 4, 5, and 6 the missense mutation Y489C was identified by heteroduplex analysis or single strand conformation analysis or both, followed by cycle sequencing of the aberrant migrating genomic fragments and further analysis at the cDNA level. In Patients 4, 5, and 6, the effect of the missense mutation Y489C at the mRNA level was identical to Patient 1, i.e., skipping of the last 62 nucleotides of exon lob. Surprisingly, three different sized transcripts were seen after RT-PCR of total RNA extracted from fresh lymphocytes from Patient 3 ( n o EBV lymphoblastoid cell line was available from this patient). RT-PCR fragments were cloned and further analyzed by cycle sequencing. In the smallest sized fragments, the mutant exon lob lacking the last 62 bp of the exon lob was followed by the correct exon 10c but hereafter the exon 11 was neatly skipped out. Skipping of exon 11 was not seen in Patients 1,4, 5, and 6. In the clones carrying the intermediate-sized transcripts, the mutant exon lob lacking the last 62-bp was found. In the largest fragments, the normal exon lob sequence was present as expected. Furthermore, between exon 4a and exon 4b, a 31-bp cryptic exon was inserted in cis with the skipping of the last 62 bp of exon lob and exon 11 in some of the mutant clones (Fig. ID) . This 31-bp cryptic exon was also seen in some mutant clones lacking only the last 62 bp of exon lob, but also in some normal clones. The same cryptic exon was recently found in a patient showing multiple splicing errors but an unknown constitutional mutation.Ih
In Patient 7, a deletion at the splice donor site of exon lob was found (IVSlOb+ZdelTAAG) and analysis of RNA extracted from a neurofibroma showed a strong shorter RT-PCR product in addition to the normal sized fragment. By cycle sequencing, it was shown that the shorter transcript was formed by the perfect splicing out of exon lob. As this splicing alteration resulted in the production ofa stable mRNA and the size of exon lob is a multiple of three, the possibility remains that this allele produces neurofibromin lacking only the 45 amino acids encoded by exon lob.
In two unrelated NF1 patients (8 and 9; one Caucasian and one African American) an identical missense mutation was identified changing the codon for Leu to Pro (L508P; 1523T>C). This missense mutation that would not be detected by the Protein Truncation Test, does not createldestroy a restriction enzyme site, but shows a specific reproducible shift in single strand conformation polymorphism analysis. Analysis of 153 unrelated Caucasian Americans and 20 unrelated Black Americans ruled out that the alteration is a polymorphism. Another 30 unrelated Caucasian Europeans were analyzed by direct sequencing of exon lob. In none was the missense mutation L508P found. Table 1 summarizes the effects on RNA splicing of the different germline mutations found in exon lob.
A novel polymorphism was identified at a CpG dinucleotide in intron 10a: IVSlOa-32C>T. We have tested 61 unrelated NF1 patients and 72 normal control persons for this polymorphism and no statistically different values were obtained between the two populations. Taking both populations together, we obtained allele frequencies of 0.68 for the IVS10a-32C allele and 0.32 for the IVS10a-32T allele. In four NF1 patients heterozygous for this polymorphism, we analyzed by RT-PCR the outcome ofthe IVS10a-32T allele with respect to the splicingof exon lob and did not observe an effect on the splicing. As the number of polyrnorphisms at the 5' end of the NFl gene is limited, this novel polymorphism, which can be detected by MoeII digestion, may be a useful tool in segregation analyses.
DISCUSSION
In this study we identified nine novel exon lob mutations in 232 unrelated NF1 patients: Y489C or 1466A>G (5X), L508P (2X), 1465-1466insC ( lX), and IVSlOb+2delTAAG (1X). Our findings indicate that exon lob is mutated in almost 4% of the NFl patients, although so far, only one missense mutation has been reported in exon lob, K505E.lh However, only two studies analyzed the complete coding region of the NF1 gene including exon lob, and the total number of patients analyzed in both studies is small, i.e., 36 patients.'O.l6 No other studies specifically looked at exon lob. Mutational analysis is hampered by the large number of exons, the wide variety of mutations, and the presence of several pseudogenes. The majority of mutations identified hitherto reside in the GAP-related domain, encoded by the exons 2 1 to 27a and in the exons downstream of this GAP-related domain. The exons lying at the 5' end of the gene have not been studied exhaustively by many groups. One reason may be that for most exons at the 5' end the available intronic sequence information was limited to the Genetics ~W e d i c i n e intron-exon boundaries, thus hampering the search for optimal primer pairs that can be used to amplify these exons, in the absence of sequences derived from pseudogenes. The novel mutations 1465insC and Y489C are different at the genomic DNA level, but both result in the formation of a premature stop codon at the mRNA level at exactly the same position through different mechanisms. Y489C illustrates that, although the mutation is reported according to the recommendations of the Nomenclature Working Group, nomenclature can be misleading. Indeed, by nature Y489C belongs to the group of splicing error mutations and not to the group of missense mutations. This unexpected iinding further stresses the importance of documenting the outcome of a mutation at the mRNA level.
It is intriguing that in 1 of the 5 patients carrying the mutation Y489C, analysis of cloned RT-PCR products showed that some mutant alleles skipped the last 62 bp of exon 10b as well as the complete exon 11. Exon 10c was retained in these clones. Skipping of exon 11 was not seen in the other patients. The cause of the exon 11 skipping in Patient 3 is unknown and may not even be due to a sequence change in the NFI gene, or it could be caused by a point change in an intron that renders this exon skipping more likely to occur. As we do not have an EBV lyrnphoblastoid cell line from this patient, we were not able to study whether this different splicing is tissue-specific. Noteworthy is that, by splice site prediction using neural networks (available at: URL: www-hgc.lbl.gov/projects/splice.html), no splice acceptor sequence can be defined for exon 11, not even after using an acceptor score cutoff of0.05. This might indicate that splicing of exon 11 is mediated through mechanisms different from splicing of those exons with a well-defined splice acceptor sequence.
The cryptic 31-bp exon between exon 4a and exon 4b was found on normal as well as on mutant cloned cDNA fragments of Patient 3. From ongoing experiments we know that this cryptic 31-bp exon is formed, albeit typically at a low level, in different cell types in NF1 patients as well as in normal persons, and hence does not appear associated with a mutation in the NFl gene per se.I7 In some neurofibromas, the cryptic 31-bp exon can be found on both alleles as well (unpublished results). A search of sequence databases showed that this 31-bp sequence was 100% homologous with a part of the NFl intron 4a. Using the splice site prediction by neural network program we found that this sequence is flanked by a splice acceptor sequence (score 0.51) tttgctgtctcatcctcacagITPLACCTTGAT-GATACTTCCC and a very strong splice donor sequence (score 0.99) TTTACAGlgtgagcaa (Fig. 1E) . The mechanisms by which this splice acceptorldonor pair is up-or downregulated is unknown, nor is it known whether this transcript is translated in vivo. The 3 1-bp cryptic exon is part of a fragment of the ancient class of Mammalian-wide Interspersed Repeat
